{
    "cancer_info": {
        "cancer_name": "Multiple HIV-associated cancers (Anal, NSCLC, Hodgkin Lymphoma, Cervical)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "CD4 count",
            "HIV viral load",
            "Hepatitis B serology",
            "Hepatitis C serology",
            "TB screening (PPD/IGRA)",
            "STI screening",
            "Digital rectal exam (DRE)",
            "High-resolution anoscopy (HRA) with biopsy",
            "Anal cytology",
            "HPV DNA testing",
            "CT scan",
            "MRI",
            "PET-CT",
            "Low-dose CT (LDCT) screening",
            "Diagnostic biopsy (bronchoscopic/CT-guided)",
            "Brain MRI",
            "Excisional lymph node biopsy",
            "Bone marrow biopsy",
            "EBV status assessment",
            "Pap smear",
            "HPV co-testing",
            "Colposcopy with biopsy",
            "MRI pelvis"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Anal Cancer: Localized (Stage I-III)",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Chemoradiation (CRT) with 5-FU + Mitomycin C",
                    "plan_details": "Definitive chemoradiation with 5-Fluorouracil + Mitomycin C",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Capecitabine-based CRT",
                    "plan_details": "Capecitabine substituting for infusional 5-FU (Phase II data)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative regimen"
                }
            ]
        },
        {
            "staging_criteria": "Anal Cancer: Metastatic/Recurrent",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Platinum-based chemotherapy",
                    "plan_details": "Cisplatin + 5-FU or Carboplatin + Paclitaxel",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Immunotherapy",
                    "plan_details": "Nivolumab or Pembrolizumab (NCI9673 phase II trial)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "NSCLC: Advanced Non-Squamous",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Carboplatin + Pemetrexed",
                    "plan_details": "Induction followed by Pemetrexed maintenance (IFCT-1001 CHIVA trial)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Immunotherapy",
                    "plan_details": "Pembrolizumab (Phase I) or Nivolumab (IFCT-1602 CHIVA2 trial)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Hodgkin Lymphoma: Advanced Stage (IIB-IV)",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "ABVD regimen",
                    "plan_details": "Doxorubicin + Bleomycin + Vinblastine + Dacarbazine",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Brentuximab vedotin + AVD",
                    "plan_details": "Brentuximab vedotin + Doxorubicin + Vinblastine + Dacarbazine (AMC 085 trial)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Alternative regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Autologous Stem Cell Transplant",
                    "plan_details": "With reduced-intensity conditioning (BMT CTN 0803/AMC 071)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Cervical Cancer: Precancer (HSIL/CIN2+)",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Excisional procedures",
                    "plan_details": "LEEP, cryotherapy, or cold-knife conization",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                }
            ]
        },
        {
            "staging_criteria": "Cervical Cancer: Invasive (Localized)",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Radical hysterectomy",
                    "plan_details": "Surgical resection",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                },
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Definitive chemoradiation",
                    "plan_details": "Cisplatin-based concurrent chemoradiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                }
            ]
        },
        {
            "staging_criteria": "Cervical Cancer: Invasive (Locally Advanced)",
            "risk_group": "HIV-infected",
            "treatment_plans": [
                {
                    "treatment_line": "Definitive treatment",
                    "patient_subgroup": "PLWH with controlled HIV",
                    "plan_name": "Concurrent chemoradiation",
                    "plan_details": "Cisplatin-based therapy (AMC trials)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "HPV: Essential causative agent for anal/cervical cancer; persistence drives carcinogenesis; used in screening. CD4 Lymphocyte Count: Predicts toxicity risk and outcomes during therapy; goal >200 cells/µL. HIV Viral Load: Sustained suppression (<200 copies/mL) associated with better outcomes. EBV: Essential pathogenic driver for Hodgkin Lymphoma. PD-L1: Predicts response to immunotherapy in NSCLC. Smoking Status: Major risk factor for lung cancer development."
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：HIV感染者癌症.txt"
}